IL162796A0 - Medicinal compositions containing ghrelin - Google Patents

Medicinal compositions containing ghrelin

Info

Publication number: IL162796A0
Authority: IL; Israel
Prior art keywords: compositions containing; medicinal compositions; containing ghrelin; ghrelin; medicinal
Prior art date: 2002-05-21

Application number

IL16279603A

Other languages

English (en)

Original Assignee

Kenji Kangawa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-21

Filing date

2003-05-21

Publication date

2005-11-20

2003-05-21 Application filed by Kenji Kangawa filed Critical Kenji Kangawa

2005-11-20 Publication of IL162796A0 publication Critical patent/IL162796A0/xx

Links

102000012004 Ghrelin Human genes 0.000 title 1
101800001586 Ghrelin Proteins 0.000 title 1
GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Immunology (AREA)
Diabetes (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Virology (AREA)
Inorganic Chemistry (AREA)
Biochemistry (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
Pregnancy & Childbirth (AREA)
Hospice & Palliative Care (AREA)

IL16279603A 2002-05-21 2003-05-21 Medicinal compositions containing ghrelin IL162796A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2002146155		2002-05-21
PCT/JP2003/006349 WO2003097083A1 (fr)	2002-05-21	2003-05-21	Compositions medicinales contenant de la ghreline

Publications (1)

Publication Number	Publication Date
IL162796A0 true IL162796A0 (en)	2005-11-20

Family

ID=29545111

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL16279603A IL162796A0 (en)	2002-05-21	2003-05-21	Medicinal compositions containing ghrelin
IL162796A IL162796A (en)	2002-05-21	2004-06-30	Medicinal compositions containing ghrelin

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL162796A IL162796A (en)	2002-05-21	2004-06-30	Medicinal compositions containing ghrelin

Country Status (11)

Country	Link
US (3)	US20060166871A1 (fr)
EP (1)	EP1506786B1 (fr)
JP (1)	JP5000848B2 (fr)
KR (1)	KR20050012224A (fr)
CN (1)	CN100411683C (fr)
AU (1)	AU2003235401B2 (fr)
BR (1)	BR0306685A (fr)
CA (1)	CA2471879C (fr)
ES (1)	ES2615484T3 (fr)
IL (2)	IL162796A0 (fr)
WO (1)	WO2003097083A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7485620B2 (en)	2001-12-18	2009-02-03	Alizé Pharma SAS	Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
US7666833B2 (en)	2001-12-18	2010-02-23	Alizé Pharma SAS	Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
WO2003097083A1 (fr)	2002-05-21	2003-11-27	Daiichi Suntory Pharma Co.,Ltd.	Compositions medicinales contenant de la ghreline
WO2004027064A2 (fr) *	2002-09-18	2004-04-01	Centre Hospitalier De L'universite De Montreal (Chum)	Analogues de ghrh
CA2543507C (fr) *	2003-10-24	2012-05-01	Theratechnologies Inc.	Utilisation de compositions de ghreline et de ghreline non acylee dans des etats pathologiques lies a l'insuline
CN1321131C (zh) *	2003-12-26	2007-06-13	李宁	猪Ghrelin衍生物及其编码基因与应用
JP2007537276A (ja) *	2004-05-11	2007-12-20	ザガバメントオブザユナイテッドステイツオブアメリカ，アズリプレゼンティッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ，ナショナルイ	グレリンを用いて炎症誘発性のサイトカイン発現を阻害する方法
WO2006023608A2 (fr) *	2004-08-18	2006-03-02	Elixir Pharmaceuticals, Inc.	Secretagogues d'hormone de croissance
CN101022822B (zh) *	2004-08-24	2012-06-27	第一三共株式会社	生理学活性肽的液体制剂
WO2006053383A1 (fr) *	2004-11-22	2006-05-26	Anadis Ltd	Préparations bioactives
US20090216117A1 (en) *	2005-04-15	2009-08-27	Shinshu University	Novel method of using triacetin and auxiliary agent for ultrasonic diagnostic examination
EP1899462B1 (fr) *	2005-07-02	2011-03-09	Arecor Limited	Systemes aqueux stables comprenant des proteines
WO2007058359A1 (fr) *	2005-11-21	2007-05-24	University Of Miyazaki	Agent therapeutique pour la peau ou agent favorisant la regeneration de la peau contenant de la ghreline, et derives de celle-ci ou substance capable d'agir en tant que principe actif sur le ghs-r1a
US20090053334A1 (en)	2006-01-31	2009-02-26	Nat. Uni. Corp. Hokkaido University	Ghrelin production promoter
EP2012809B1 (fr) *	2006-03-10	2013-05-22	Ipsen Pharma	Utilisation d'un agoniste de la ghréline pour améliorer les effets cataboliques d'un traitement aux glucocorticoïdes
US7763707B2 (en)	2006-03-13	2010-07-27	Liat Mintz	Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
BRPI0708895A2 (pt)	2006-03-13	2011-06-28	Liat Mintz	uso de variante de junção de grelina para tratar caquexia e/ou anorexia e/ou anorexia-caquexia e/ou subnutrição e/ou lipodistrofia e/ou atrofia muscular e/ou estimulação do apetite
AU2007300526B2 (en) *	2006-09-27	2011-07-21	Ipsen Pharma S.A.S.	Analogs of ghrelin substituted at the N-terminal
GB0700523D0 (en) *	2007-01-11	2007-02-21	Insense Ltd	The Stabilisation Of Proteins
AU2008257448B9 (en)	2007-05-31	2013-07-11	Alize Pharma Sas	Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
US8318664B2 (en)	2007-05-31	2012-11-27	Alize Pharma Sas	Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
KR20100056507A (ko) *	2007-09-11	2010-05-27	몬도바이오테크 래보래토리즈 아게	치료제로서의 펩티드 ｐｒｏ－ｇｌｙ－ｔｈｒ－ｃｙｓ－ｇｌｕ－ｉｌｅ－ｃｙｓ－ａｌａ－ｔｙｒ－ａｌａ－ａｌａ－ｃｙｓ－ｔｈｒ－ｇｌｙ－ｃｙｓ의 용도
WO2009133408A2 (fr)	2008-05-01	2009-11-05	Arecor Limited	Formulation de protéines
US8476408B2 (en)	2008-06-13	2013-07-02	Alize Pharma Sas	Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
EP2328607A1 (fr)	2008-07-16	2011-06-08	Arecor Limited	Formulation stable d'une protéine thérapeutique
EP2483406A2 (fr)	2009-09-30	2012-08-08	President and Fellows of Harvard College	Procédés de modulation de l'autophagie par la modulation de produits géniques inhibant l'autophagie
US20130142809A1 (en)	2011-11-23	2013-06-06	Andrew A. Welcher	METHODS OF TREATMENT USING AN IFN gamma INHIBITOR
HRP20190062T1 (hr)	2011-12-15	2019-03-08	Millendo Therapeutics Sas	Fragmenti neaciliranog grelina za uporabu u liječenju prader-willi sindroma
TW201336864A (zh) *	2012-02-03	2013-09-16	Zealand Pharma As	胃飢餓素（ｇｈｒｅｌｉｎ）類似物
FR2987268B1 (fr)	2012-02-28	2014-07-11	Ammtek	Formulations liquides de sulfamides hypoglycemiants
CA2914979C (fr)	2013-07-16	2022-12-06	Liat Mintz	Variante d'epissage de la ghreline pour le traitement d'une lesion neuronale, d'une maladie neurodegenerative, de la maladie de parkinson, de la maladie d'alzheimer et/ou de la de pression
US9119832B2 (en)	2014-02-05	2015-09-01	The Regents Of The University Of California	Methods of treating mild brain injury
US10265383B2 (en)	2014-09-09	2019-04-23	The Feinstein Institute For Medical Research	Treatment of radiation injury using ghrelin
JP6580581B2 (ja) *	2014-09-27	2019-09-25	大日本住友製薬株式会社	注射用医薬組成物
US20180296647A1 (en) *	2015-10-14	2018-10-18	Kurume University	Prophylactic and therapeutic agent for rett syndrome (rtt) comprising ghrelin as active ingredient
WO2017075535A1 (fr)	2015-10-28	2017-05-04	Oxeia Biopharmaceuticals, Inc.	Méthodes de traitement de troubles neurodégénératifs
JP2018169273A (ja) *	2017-03-29	2018-11-01	東ソー株式会社	ペプチドの吸着抑制剤
PL3817751T3 (pl) *	2018-07-03	2025-09-08	Fennec Pharmaceuticals, Inc.	Postacie użytkowe bezwodnego tiosiarczanu sodu
JP2022543956A (ja) *	2019-05-07	2022-10-17	フロンティアバイオテクノロジーズインク．	安定なアルブビルチド組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0651637B2 (ja) *	1985-03-28	1994-07-06	エーザイ株式会社	ペプタイドの吸着防止組成物
JPS62238298A (ja) *	1986-04-08	1987-10-19	Sanraku Inc	新規アントラサイクリン抗生物質ｄｃｐ−１及び２
JPH0669956B2 (ja) *	1988-09-30	1994-09-07	旭化成工業株式会社	ポリペプタイド類の吸着防止剤
DE4126983A1 (de) *	1991-08-15	1993-02-18	Boehringer Mannheim Gmbh	Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
SE9300105D0 (sv)	1993-01-15	1993-01-15	Kabi Pharmacia Ab	Stable protein solution
US5482931A (en) *	1993-06-29	1996-01-09	Ferring Ab	Stabilized pharmaceutical peptide compositions
DE4340781C3 (de)	1993-11-30	2000-01-27	Novartis Ag	Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
TW426523B (en)	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
US5843903A (en) *	1995-11-27	1998-12-01	The Administrators Of The Tulane Educational Fund	Targeted cytotoxic anthracycline analogs
US5780431A (en)	1996-09-20	1998-07-14	Neurobiological Technologies, Inc.	Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US5998381A (en) *	1996-12-06	1999-12-07	Ophidian Pharmaceuticals, Inc.	Compounds that bind bacterial pili
CN1317967A (zh)	1998-09-17	2001-10-17	伊莱利利公司	蛋白质制剂
KR100827973B1 (ko) *	1999-07-23	2008-05-21	겐지 간가와	신규 펩티드
WO2001087322A2 (fr)	2000-05-17	2001-11-22	Bionebraska, Inc.	Preparations pharmaceutiques peptidiques
AU2001259056A1 (en) *	2000-05-17	2001-11-26	Eli Lilly And Company	Method for selectively inhibiting ghrelin action
AU785444B2 (en)	2000-05-19	2007-06-14	Jefferson Pharmaceuticals, Llc	Peptide pharmaceutical formulations
CA2411667A1 (fr)	2000-05-30	2001-12-06	Merck & Co. Inc.	Analogues de la ghreline
AU2002316811A1 (en)	2001-06-28	2003-03-03	Novo Nordisk A/S	Stable formulation of modified glp-1
WO2003084983A1 (fr) *	2002-04-11	2003-10-16	Daiichi Suntory Pharma Co., Ltd.	Procede de production d'un peptide modifie
WO2003097083A1 (fr)	2002-05-21	2003-11-27	Daiichi Suntory Pharma Co.,Ltd.	Compositions medicinales contenant de la ghreline

2003
- 2003-05-21 WO PCT/JP2003/006349 patent/WO2003097083A1/fr not_active Ceased
- 2003-05-21 KR KR10-2004-7010362A patent/KR20050012224A/ko not_active Ceased
- 2003-05-21 EP EP03752939.3A patent/EP1506786B1/fr not_active Expired - Lifetime
- 2003-05-21 CN CNB038028301A patent/CN100411683C/zh not_active Expired - Lifetime
- 2003-05-21 BR BR0306685-1A patent/BR0306685A/pt not_active IP Right Cessation
- 2003-05-21 JP JP2004505079A patent/JP5000848B2/ja not_active Expired - Lifetime
- 2003-05-21 ES ES03752939.3T patent/ES2615484T3/es not_active Expired - Lifetime
- 2003-05-21 US US10/500,561 patent/US20060166871A1/en not_active Abandoned
- 2003-05-21 IL IL16279603A patent/IL162796A0/xx active IP Right Grant
- 2003-05-21 CA CA2471879A patent/CA2471879C/fr not_active Expired - Lifetime
- 2003-05-21 AU AU2003235401A patent/AU2003235401B2/en not_active Expired
2004
- 2004-06-30 IL IL162796A patent/IL162796A/en unknown
2007
- 2007-07-25 US US11/878,532 patent/US8440628B2/en not_active Expired - Fee Related
2012
- 2012-03-06 US US13/413,581 patent/US8518893B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2003235401A1 (en)	2003-12-02
US8440628B2 (en)	2013-05-14
JP5000848B2 (ja)	2012-08-15
WO2003097083A1 (fr)	2003-11-27
BR0306685A (pt)	2005-04-26
CN1622822A (zh)	2005-06-01
CA2471879C (fr)	2014-02-25
JPWO2003097083A1 (ja)	2005-10-06
EP1506786B1 (fr)	2016-11-23
KR20050012224A (ko)	2005-01-31
US20120264691A1 (en)	2012-10-18
EP1506786A4 (fr)	2009-07-29
ES2615484T3 (es)	2017-06-07
CN100411683C (zh)	2008-08-20
US20060166871A1 (en)	2006-07-27
US20080081787A1 (en)	2008-04-03
EP1506786A1 (fr)	2005-02-16
US8518893B2 (en)	2013-08-27
CA2471879A1 (fr)	2003-11-27
AU2003235401B2 (en)	2008-09-25
IL162796A (en)	2011-01-31

Legal Events

Date	Code	Title	Description
2011-06-30	FF	Patent granted

Publication	Publication Date	Title
IL162796A (en)	2011-01-31	Medicinal compositions containing ghrelin
GB2389530B (en)	2007-01-10	Pharmaceutical compositions
AU2003291103A8 (en)	2004-06-15	Pharmaceutical composition
GB0204719D0 (en)	2002-04-17	Medicinal compounds
GB0220730D0 (en)	2002-10-16	Medicinal compounds
GB0225030D0 (en)	2002-12-04	Medicinal compounds
IL164547A0 (en)	2005-12-18	Pharmaceutical composition
AU2003276549A8 (en)	2004-06-15	Pharmaceutical compositions containing a biguanide-glitazone combination
GB2391473B (en)	2004-07-07	Pharmaceutical compositions
IL165878A0 (en)	2006-01-15	Pharmaceutical composition
GB0229258D0 (en)	2003-01-22	Medicinal compositions
GB0213481D0 (en)	2002-07-24	Pharmaceutical compositions
EP1600445A4 (fr)	2008-06-11	Preparation curative
EP1480649A4 (fr)	2006-04-26	Compositions pharmaceutiques stables
PL370907A1 (en)	2005-05-30	Pharmaceutical compositions
GB0217703D0 (en)	2002-09-11	Pharmaceutical composition
EP1547593A4 (fr)	2009-12-23	Composition medicinale
GB0213267D0 (en)	2002-07-24	Pharmaceutical composition
GB0220095D0 (en)	2002-10-09	Pharmaceutical composition
GB0227342D0 (en)	2002-12-31	Pharmaceutical composition
GB0214491D0 (en)	2002-08-07	Pharmaceutical composition
GB0213306D0 (en)	2002-07-24	Pharmaceutical composition
GB0213305D0 (en)	2002-07-24	Pharmaceutical composition
GB0211355D0 (en)	2002-06-26	Pharmaceutical composition
GB0225042D0 (en)	2002-12-04	Pharmaceutical composition